Black Rock Inc. Viridian Therapeutics, Inc.\De Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
A detailed history of Black Rock Inc. transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Black Rock Inc. holds 4,773,622 shares of VRDN stock, worth $69.1 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,773,622
Previous 3,812,630
25.21%
Holding current value
$69.1 Million
Previous $66.8 Million
6.97%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding VRDN
# of Institutions
189Shares Held
79.6MCall Options Held
92.2KPut Options Held
55.2K-
Deep Track Capital, LP Greenwich, CT5.38MShares$77.9 Million2.54% of portfolio
-
Kynam Capital Management, LP Princeton, NJ4.7MShares$68 Million5.34% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.56MShares$66 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$56.2 Million12.64% of portfolio
-
Commodore Capital LP New York, NY3.6MShares$52.1 Million4.75% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $577M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...